FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2962507701> ?p ?o ?g. }

• W2962507701 endingPage "S158" @default.
• W2962507701 startingPage "S150" @default.
• W2962507701 abstract "Growth hormone (GH)-secreting pituitary adenomas, responsible for the development of acromegaly, are the second most frequent type of secreting pituitary adenomas and are characterized by very variable T2-weighted signal intensity on pituitary magnetic resonance imaging (MRI). Previous data have demonstrated a correlation between T2-weighted tumor signal intensity and response to therapy with conventional somatostatin analogs (SSA) in patients with acromegaly. The aim of the current retrospective study was to investigate the correlation between the T2-weighted tumor signal on pituitary MRI and both biochemical and radiological response to first-line SSA therapy.Twenty-two naive patients with acromegaly were eligible for the study (14 females and 8 males, mean age ± SD: 58.8±15.74). A biochemical evaluation (GH and IGF-I levels) and an MRI assessment (volume and signal intensity analysis of adenoma) were conducted in each patient at diagnosis and after 12 months of SSA therapy.On diagnostic pituitary MRI, 16 (72.7%) adenomas were T2- hypointense and 6 (27.2%) T2-hyperintense. After 12 months of SSA therapy, IGF-I levels decreased by more than 50% from baseline in 62.5% of patients with T2-hypointense and 33.3% of patients with T2- hyperintense tumor signal, respectively (P=0.03). Moreover, GH levels decreased by more than 80% from baseline in 81.3% and 33.3% of patients with T2-hypointense and T2-hyperintense tumor signal (P=0.02). A significant tumor volume reduction (≥20%) was observed in 75% of the T2-hypointense and 33.3% of the T2-hyperintense adenomas (P=0.001).In naive patients with acromegaly, first-line SSA therapy is associated with a better biochemical response and greater tumor shrinkage in T2-hypointense compared to T2-hyperintense adenomas. Therefore, T2-weighted sequences of pituitary MRI can help to classify GH-secreting pituitary adenomas into a T2-hypointense and T2-hyperintense type and, therefore, to identify patients who can better respond to first-line SSA therapy." @default.
• W2962507701 created "2019-07-23" @default.
• W2962507701 creator A5003544129 @default.
• W2962507701 creator A5026430625 @default.
• W2962507701 creator A5027854674 @default.
• W2962507701 creator A5028155924 @default.
• W2962507701 creator A5051019315 @default.
• W2962507701 creator A5061164953 @default.
• W2962507701 creator A5061899488 @default.
• W2962507701 creator A5063936702 @default.
• W2962507701 date "2019-09-01" @default.
• W2962507701 modified "2023-09-27" @default.
• W2962507701 title "Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas" @default.
• W2962507701 cites W1870125158 @default.
• W2962507701 cites W1876291110 @default.
• W2962507701 cites W1905322309 @default.
• W2962507701 cites W1907174987 @default.
• W2962507701 cites W1985295901 @default.
• W2962507701 cites W1985508697 @default.
• W2962507701 cites W1991041813 @default.
• W2962507701 cites W1998538661 @default.
• W2962507701 cites W2006343062 @default.
• W2962507701 cites W2017073193 @default.
• W2962507701 cites W2021436231 @default.
• W2962507701 cites W2038754029 @default.
• W2962507701 cites W2047245583 @default.
• W2962507701 cites W2047333088 @default.
• W2962507701 cites W2081324142 @default.
• W2962507701 cites W2100301546 @default.
• W2962507701 cites W2101675454 @default.
• W2962507701 cites W2108052917 @default.
• W2962507701 cites W2118822979 @default.
• W2962507701 cites W2121103313 @default.
• W2962507701 cites W2124316389 @default.
• W2962507701 cites W2132094049 @default.
• W2962507701 cites W2152811513 @default.
• W2962507701 cites W2155465275 @default.
• W2962507701 cites W2155465680 @default.
• W2962507701 cites W2158629056 @default.
• W2962507701 cites W2159303404 @default.
• W2962507701 cites W2216889155 @default.
• W2962507701 cites W2510776513 @default.
• W2962507701 cites W2512017501 @default.
• W2962507701 cites W2521212328 @default.
• W2962507701 cites W2551815891 @default.
• W2962507701 cites W2586526973 @default.
• W2962507701 cites W2588897318 @default.
• W2962507701 cites W2755648165 @default.
• W2962507701 cites W2766825024 @default.
• W2962507701 cites W4211191881 @default.
• W2962507701 doi "https://doi.org/10.21037/gs.2019.06.04" @default.
• W2962507701 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6755952" @default.
• W2962507701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31559182" @default.
• W2962507701 hasPublicationYear "2019" @default.
• W2962507701 type Work @default.
• W2962507701 sameAs 2962507701 @default.
• W2962507701 citedByCount "13" @default.
• W2962507701 countsByYear W29625077012019 @default.
• W2962507701 countsByYear W29625077012020 @default.
• W2962507701 countsByYear W29625077012021 @default.
• W2962507701 countsByYear W29625077012022 @default.
• W2962507701 crossrefType "journal-article" @default.
• W2962507701 hasAuthorship W2962507701A5003544129 @default.
• W2962507701 hasAuthorship W2962507701A5026430625 @default.
• W2962507701 hasAuthorship W2962507701A5027854674 @default.
• W2962507701 hasAuthorship W2962507701A5028155924 @default.
• W2962507701 hasAuthorship W2962507701A5051019315 @default.
• W2962507701 hasAuthorship W2962507701A5061164953 @default.
• W2962507701 hasAuthorship W2962507701A5061899488 @default.
• W2962507701 hasAuthorship W2962507701A5063936702 @default.
• W2962507701 hasBestOaLocation W29625077011 @default.
• W2962507701 hasConcept C126322002 @default.
• W2962507701 hasConcept C126838900 @default.
• W2962507701 hasConcept C134018914 @default.
• W2962507701 hasConcept C142724271 @default.
• W2962507701 hasConcept C143409427 @default.
• W2962507701 hasConcept C2776297358 @default.
• W2962507701 hasConcept C2777428134 @default.
• W2962507701 hasConcept C2777433750 @default.
• W2962507701 hasConcept C2779318953 @default.
• W2962507701 hasConcept C2984496839 @default.
• W2962507701 hasConcept C2989005 @default.
• W2962507701 hasConcept C71315377 @default.
• W2962507701 hasConcept C71924100 @default.
• W2962507701 hasConceptScore W2962507701C126322002 @default.
• W2962507701 hasConceptScore W2962507701C126838900 @default.
• W2962507701 hasConceptScore W2962507701C134018914 @default.
• W2962507701 hasConceptScore W2962507701C142724271 @default.
• W2962507701 hasConceptScore W2962507701C143409427 @default.
• W2962507701 hasConceptScore W2962507701C2776297358 @default.
• W2962507701 hasConceptScore W2962507701C2777428134 @default.
• W2962507701 hasConceptScore W2962507701C2777433750 @default.
• W2962507701 hasConceptScore W2962507701C2779318953 @default.
• W2962507701 hasConceptScore W2962507701C2984496839 @default.
• W2962507701 hasConceptScore W2962507701C2989005 @default.
• W2962507701 hasConceptScore W2962507701C71315377 @default.
• W2962507701 hasConceptScore W2962507701C71924100 @default.
• W2962507701 hasIssue "S3" @default.

• next